Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter
This article was originally published in The Tan Sheet
Executive Summary
The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery
You may also be interested in...
Petition To Restrict St. John’s Wort Draws Fire From Industry
Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.
Petition To Restrict St. John’s Wort Draws Fire From Industry
Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.
Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman
Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee